17751-24-5

Usage

Uses

Used in Medicinal Chemistry:
(2,6-Difluoro-benzyl)-urea is used as a chemical intermediate for the development of new pharmaceuticals due to its potential diverse biological activities and the versatility of urea derivatives in medicinal applications.
Used in Pharmaceutical Development:
(2,6-Difluoro-benzyl)-urea is utilized as a key component in the synthesis of various drug candidates, aiming to enhance their therapeutic effects and target specific biological pathways for the treatment of different diseases.
Further research is necessary to fully understand the potential uses and effects of (2,6-Difluoro-benzyl)-urea, as its applications in different industries and therapeutic areas may be extensive.

InChI:InChI=1/C8H8F2N2O/c9-6-2-1-3-7(10)5(6)4-12-8(11)13/h1-3H,4H2,(H3,11,12,13)

Upstream product

• 69385-30-4 2,6-difluorobenzylamine 
• 57-13-6 urea 

Downstream Products

• 352303-65-2 N-1-(2,6-difluorobenzyl)-6-methyluracil 
• 618914-13-9 1-(2,6-difluorobenzyl)-3-(3-oxobutyryl)urea 
• 352290-51-8 3-(2-amino-1-methyl-ethyl)-1-(2,6-difluoro-benzyl)-5-(3-methoxy-phenyl)-6-methyl-1H-pyrimidine-2,4-dione 
• 618902-03-7 3-(2-amino-1-methyl-ethyl)-1-(2,6-difluoro-benzyl)-5-(3-methoxy-phenyl)-6-methyl-1H-pyrimidine-2,4-dione 
• 352290-55-2 3-(2-amino-propyl)-1-(2,6-difluoro-benzyl)-5-(3-methoxy-phenyl)-6-methyl-1H-pyrimidine-2,4-dione 
• 352290-54-1 3-(2-amino-propyl)-1-(2,6-difluoro-benzyl)-5-(3-methoxy-phenyl)-6-methyl-1H-pyrimidine-2,4-dione 
• 352303-74-3 3-[2-N-Boc-amino-1-(R)-methylethyl]-5-bromo-1-(2,6-difluorobenzyl)-6-methyluracil 
• 618902-01-5 3-[2-N-Boc-amino-1-(S)-methylethyl]-5-bromo-1-(2,6-difluorobenzyl)-6-methyluracil 
• 675605-94-4 5-bromo-1-(2,6-difluorobenzyl)-3-[2-(S)-N-Boc-aminopropyl]-6-methyluracil 
• 352303-75-4 5-bromo-1-(2,6-difluorobenzyl)-3-[2-(R)-N-Boc-aminopropyl]-6-methyluracil 
• 352300-01-7 3-(2-benzylamino-propyl)-1-(2,6-difluoro-benzyl)-5-(3-methoxy-phenyl)-6-methyl-1H-pyrimidine-2,4-dione 
• 352299-99-1 3-(2-benzylamino-propyl)-1-(2,6-difluoro-benzyl)-5-(3-methoxy-phenyl)-6-methyl-1H-pyrimidine-2,4-dione 
• 618914-18-4 1-(2,6-difluoro-benzyl)-5-(3-methoxy-phenyl)-6-methyl-3-{2-[(pyridin-2-ylmethyl)-amino]-propyl}-1H-pyrimidine-2,4-dione 
• 618914-19-5 1-(2,6-difluoro-benzyl)-5-(3-methoxy-phenyl)-6-methyl-3-{2-[(pyridin-2-ylmethyl)-amino]-propyl}-1H-pyrimidine-2,4-dione 

Relevant academic research and scientific papers

Discovery of sodium R-(+)-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6- [trifluoromethyl]-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl] -1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor

The discovery of novel uracil phenylethylamines bearing a butyric acid as potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonists is described. A major focus of this optimization was to improve the CYP3A4 inhibition liability of these uracils while maintaining their GnRH-R potency. R-4-{2-[5-(2-Fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl) -4-methyl-2,6-dioxo-3,6-dihy-dro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyric acid sodium salt, 10b (elagolix), was identified as a potent and selective hGnRH-R antagonist. Oral administration of 10b suppressed luteinizing hormone in castrated macaques. These efforts led to the identification of 10b as a clinical compound for the treatment of endometriosis.

Synthesis and Structure-Activity Relationships of 1-Arylmethyl-5-aryl-6-methyluracils as Potent Gonadotropin-Releasing Hormone Receptor Antagonists

Based on the SAR from bicyclic gonadotropin-releasing hormone (GnRH) antagonists such as 6-aminomethyl-7-aryl-pyrrolo [1,2-a] pyrimid-4-ones (5) and 2-aryl-3-aminomethyl-imidazolo-[1,2-a]pyrimid-5-ones (6a,b), a series of novel uracil compounds (8) were d

Synthesis and structure-activity relationships of uracil derived human GnRH receptor antagonists: (R)-3-[2-(2-amino)phenethyl]-1-(2,6-difluorobenzyl)-6- methyluracils containing a substituted thiophene or thiazole at C-5

The design and synthesis of a number of 5-thiazolyl and 5-thienyl substituted uracils is described and results from SAR studies are summarized. The best compound showed Ki = 2 nM. The synthesis of a series of (R)-3-[2-(2-amino)phenethyl]-1-(2,6

Synthesis and structure-activity relationships of 1-arylmethyl-3-(2-aminopropyl)-5-aryl-6-methyluracils as potent GnRH receptor antagonists

The novel synthesis and SAR studies of 6-methyluracils as human GnRH receptor antagonists are discussed. Introduction of a small methyl substituent at the β-position from N3 of the uracil improved the GnRH binding potency by 5- to 10-fold. The best compou

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, Q, R1, R2, R3a, R3b, R4, R5, R6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.